# Goldline Pharmaceutical Limited: IPO analysis > Goldline Pharmaceutical Limited (CIN U51397MH2004PLC147806) has filed a Prospectus with SEBI for an IPO. In FY25 it reported revenue of ₹28 Cr (+19.1% on FY24) and a net profit of ₹2.2 Cr. Promoters hold 79.7% before the IPO. Our fact-check of its claims found no medium or high concerns across 67 claims checked. - Page: https://ipo.innerkore.com/company/U51397MH2004PLC147806/goldline-pharmaceutical-limited/ - CIN: U51397MH2004PLC147806 - Last updated: 11 Jun 2026 ## Key facts - **Company:** Goldline Pharmaceutical Limited - **CIN:** U51397MH2004PLC147806 - **Filing stage:** Prospectus - **Latest SEBI filing:** 11 Jun 2026 - **Lot size:** 3000 shares - **Bidding opens:** 12 May 2026 - **Bidding closes:** 14 May 2026 - **Listing on:** BSE - **Revenue FY25:** ₹28 Cr - **Revenue growth:** +19.1% - **Net profit FY25:** ₹2.2 Cr - **Revenue CAGR FY23 to FY25:** 18.9% - **Promoter holding (pre-IPO):** 79.7% - **Lead managers:** CUMULATIVE CAPITAL PRIVATE LIMITED - **Registrar:** BIGSHARE SERVICES PRIVATE LIMITED - **Fact-check flags:** 0 high, 0 medium, 0 low ## Key signals (read from the filing; not investment advice) - **Growth** (look closer): 18.9% a year. Sales FY23 to FY25; latest year +19.1%. - **Profitability** (look closer): 7.9% net margin. FY25; operating margin improving. - **Debt** (looks fine): 0.38x equity. ₹11 crore borrowed at the end of FY25. - **Profit into cash** (looks fine): 105% of profit. Operations brought in ₹2.3 crore against ₹2.2 crore of profit in FY25. - **One-off income** (looks fine): 0% of profit. Other and one-off income is 0% of pre-tax profit. - **Red flags** (looks fine): None serious. 67 claims checked: 0 high, 0 medium concern. ## Financial snapshot (₹ crore unless stated; consolidated) | | FY23 | FY24 | FY25 | 9M Dec-25 | |---|---:|---:|---:|---:| | Sales | 20 | 24 | 28 | 21 | | Sales growth | – | 18.7% | 19.1% | – | | Operating profit | 2.2 | 4.3 | 5.8 | 4.2 | | Operating margin | 11.1% | 18.3% | 20.8% | 19.4% | | Net profit | 0.26 | 1.8 | 2.2 | 2.8 | | Net margin | 1.3% | 7.7% | 7.9% | 13.2% | | Net worth | 22 | 26 | 29 | 30 | | Borrowings | 11 | 11 | 11 | 9.5 | | Return on equity | 1.2% | 6.9% | 7.6% | – | ## Use of proceeds (fresh issue) - Repayment of all or a portion of certain outstanding borrowings availed by our company: ₹8.4 crore - General corporate purposes: ₹1.7 crore ## Fact-checked claims - **NONE** (PromoterBackground): Amol Laxmikant Mujumdar was a subscriber to MoA Cash on the date of incorporation.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Amol Laxmikant Mujumdar was a subscriber to the Memorandum of Association (MoA) Cash on the date of incorporation. - **NONE** (SubsidiaryPerformance): Private final consumption expenditure (PFCE) grew by 4.0 per cent in real terms in FY24.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Private final consumption expenditure (PFCE) grew by 4.0 per cent in real terms in FY24 for Goldline Pharmaceutical Limited. - **NONE** (SubsidiaryPerformance): Construction activities showed increased momentum and registered a growth of 9.9 percent in FY24 due to infrastructure buildout and real estate demand.. No current web search results were found to corroborate, contradict, update, or provide any new information regarding the claim about the 9.9 percent growth in construction activities for Goldline Pharmaceutical Limited in FY24. - **NONE** (SubsidiaryPerformance): Manufacturing Gross Value Added (GVA) grew by 9.9 percent in FY24, benefiting from reduced input prices.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Manufacturing Gross Value Added (GVA) grew by 9.9 percent in FY24 due to reduced input prices. - **NONE** (SubsidiaryPerformance): Gross fixed capital formation (GFCF) by the private sector in machinery and equipment and intellectual property products grew by 38% between FY21 and FY23.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim about the growth of gross fixed capital formation by the private sector in machinery and equipment and intellectual property products by 38% between FY21 and FY23. - **NONE** (SubsidiaryPerformance): Investment in Machinery and Equipment and Intellectual Property Products grew cumulatively by only 35% in the four years to FY23.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that investment in machinery and equipment and intellectual property products grew cumulatively by only 35% in the four years to FY23. - **NONE** (SubsidiaryPerformance): Cumulative growth in private sector non-financial Gross Fixed Capital Formation (GFCF) was 52% between FY19 and FY23.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim about the cumulative growth in private sector non-financial Gross Fixed Capital Formation (GFCF) between FY19 and FY23. - **NONE** (SubsidiaryPerformance): Foreign Direct Investment showed a slight decline in dollar inflows in FY24 compared to FY23, in line with global trends.. No current web search results were found to corroborate, contradict, or provide any information regarding the claim about the decline in foreign direct investment dollar inflows for Goldline Pharmaceutical Limited in FY24 compared to FY23. - **NONE** (PromoterBackground): Amol Laxmikant Mujumdar held a share transfer from Arun Gupta HUF on July 13, 2013.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Amol Laxmikant Mujumdar held a share transfer from Arun Gupta HUF on July 13, 2013. - **NONE** (PromoterBackground): A bonus issue of 2:1 was conducted on June 05, 2024, with consideration other than cash, resulting in transfers to Reema Patel, Charmi Patel, Meena Patel, Krunal Shirshikar, and Abhisha Patel.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim about a bonus issue conducted by Goldline Pharmaceutical Limited on June 05, 2024, involving the specified individuals. - **NONE** (PromoterBackground): Swapan Premprakash Khandelwal transferred equity shares from Girish on May 28, 2011.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that Swapan Premprakash Khandelwal transferred equity shares from Girish on May 28, 2011. - **NONE** (PromoterBackground): A bonus issue of 2:1 was conducted on June 05, 2024, with consideration other than cash.. No current web search results were found to corroborate, contradict, update, or provide any information regarding the claim that a 2:1 bonus issue was conducted on June 05, 2024, with non-cash consideration. ## Common questions ### How big is the Goldline Pharmaceutical Limited IPO? The size of the Goldline Pharmaceutical Limited IPO is not stated in a form we could read from its Prospectus. Draft filings often leave amounts blank until the Red Herring Prospectus. ### What are Goldline Pharmaceutical Limited's revenue and profit? Goldline Pharmaceutical Limited reported revenue from operations of ₹28 Cr in FY25, +19.1% versus FY24. Net profit was ₹2.2 Cr (FY24: ₹1.8 Cr). Revenue grew at a compound rate of 18.9% a year from FY23 to FY25. Figures are read from the Prospectus, as printed there. ### How much do promoters own in Goldline Pharmaceutical Limited? Promoters hold 79.7% of Goldline Pharmaceutical Limited before the IPO. ### How will Goldline Pharmaceutical Limited use the IPO money? The fresh-issue proceeds are earmarked for: Repayment of all or a portion of certain outstanding borrowings availed by our company (₹8.4 Cr); General corporate purposes (₹1.7 Cr). ### What are the red flags in Goldline Pharmaceutical Limited's Prospectus? We fact-checked 67 claims from the filing against the open web: 0 raised a high concern, 0 medium and 0 low. This is an automated screen, not a verdict; each finding links to its sources. ### What does Goldline Pharmaceutical Limited do? Forget the hype: our investigation into the Goldline Pharmaceutical Limited IPO reveals a critical gap in the public record. We found absolutely no evidence to confirm whether Amol Laxmikant Mujumdar was a subscriber to the Memorandum of Association cash on the day the company was incorporated. ### Who manages the Goldline Pharmaceutical Limited IPO? Book running lead managers: CUMULATIVE CAPITAL PRIVATE LIMITED. Registrar to the offer: BIGSHARE SERVICES PRIVATE LIMITED. Shares are proposed to list on BSE. ### Where can I read the original Goldline Pharmaceutical Limited IPO documents? All 2 filings for Goldline Pharmaceutical Limited (Prospectus) are listed on this page with links to the original PDFs on SEBI's website. Every page reference cites the exact page of the source document. ## Source documents - [Goldline Pharmaceutical Limited](https://www.sebi.gov.in/sebi_data/attachdocs/jun-2026/1781163008253_1280.pdf) (Prospectus, filed 11 Jun 2026) - [Goldline Pharmaceutical Limited](https://www.sebi.gov.in/sebi_data/attachdocs/jun-2026/1781177415072_1285.pdf) (Prospectus, filed 11 Jun 2026) --- Source: InnerKore IPO (https://ipo.innerkore.com/). Read from public SEBI filings by automated extraction; check the linked documents. Not investment advice.